If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
166
results.
Updated on
14/09/2026 [06:57:00]
Absstract of: WO2026184355A1
The present application relates to a method for online monitoring of vital sign parameters of a host and a multi-working-electrode system, which can improve the accuracy of glucose monitoring. The method comprises: using a first working electrode to acquire a first vital sign parameter of a host; using a second working electrode to acquire a second vital sign parameter of the host; and acquiring, on the basis of the first vital sign parameter and the second vital sign parameter, a target glucose concentration of the host. The first working electrode and the second working electrode are arranged on the same substrate, and can acquire the first vital sign parameter and the second vital sign parameter, respectively, at different depths of the host's tissue independently of each other. The two working electrodes can effectively determine analyte concentrations at different depths, which, combined with the vital sign parameters generated by the different working electrodes, can comprehensively provide more reliable continuous monitoring results, thereby improving the accuracy of monitoring.
Absstract of: WO2026187796A1
A sensor measures a physiological condition (e.g., glucose) of a user. The sensor also facilitates an assessment of a transient sensor signal skew that occurs to the sensor's signal. The transient sensor signal skew occurs as a result of an immune response or bleeding from the user's body, where the immune response or bleeding occurs in response to an insertion and/or subsequent retained presence of the sensor tail in the user's body. The sensor includes an optical sensor. As a result of an ointment being applied to a top layer of the user's skin, the skin becomes at least partially translucent. The optical sensor is directed towards the top layer of the skin onto which the ointment was applied. The optical sensor is structured to generate images of the translucent skin. The images reflect inflammation occurring under the skin. The transient sensor skew is based on the detected inflammation.
Absstract of: US20260269465A1
0000 A medical device such as an automated medicament delivery device for automated administration of medicament to a user-body or an analyte sensor such as a continuous glucose monitor for detecting analyte levels in a user-body are disclosed. The automated medicament delivery device includes an antenna, a communication chip, and a gain control circuit. The communication chip configured for operation of the antenna in at least two selectable modes including a high-gain mode and a low-gain mode. The high-gain mode and the low-gain mode of the antenna at least partially based on a state of a gain control circuit operatively coupling the communication chip with the antenna. The antenna, utilizing the gain control circuit, operable in the low-gain mode during performance of a pairing operation with a separate device and operable in the high-gain mode during ongoing external communication.
Absstract of: WO2026187363A1
A method of multi-analyte analysis includes applying an electrical test sequence to a sample applied to a reagent in an electrochemical sensing device, generating a measurement of a primary analyte in the sample based on a response to the electrical test sequence, generating a classification of a secondary' analyte in the sample based on a least one feature extracted from the response to the electrical test sequence provided to a machine-learning model, the second analyte being different titan the first analyte, and generating at least one output corresponding to the measurement of the primary' analyte and the classification of the secondary analyte. Particular analytes of interest include glucose measurement and ketone classification.
Absstract of: WO2026187966A1
A wearable smart insole for a user having foot having a planter arch and a medial plantar artery (MPA) along the plantar arch is provided. The insole has at least one optical sensor disposed in the insole along the MPA, a power handling circuit, an energy storage module operatively coupled with the power handing circuit to provide power to the optical sensor. The optical sensor is disposed along the MPA. in the insole and provides a signal for obtaining heart rate data, blood oxygen saturation data and blood glucose measurements. Two optical sensors may be provided along the MPA to provide signals for calculating blood pressure. A third optical sensor may be provided along the lateral plantar artery to provide signals to detect diabetes or arterial disease.
Absstract of: US20260268225A1
Techniques for determining insulin therapy are described. The techniques include obtaining patient characteristic information and one or more target therapy efficacy metrics representative of a desired clinical outcome for a current patient. The techniques may further include providing the patient characteristic information and the one or more target therapy efficacy metrics as an input to a machine-learning model, wherein the machine-learning model has been trained to determine an insulin delivery therapy that will cause the current patient to achieve the desired clinical outcome represented in the one or more target therapy efficacy metrics based on the current patient having the patient characteristic information. The techniques may further include determining the insulin delivery therapy based on an output of the machine-learning model. The techniques may further include outputting information indicative of the determined insulin delivery therapy.
Absstract of: WO2026186968A1
The present invention relates to a composition for restoring pancreatic beta-cell function, the composition comprising intestinal organoid-derived exosomes. The intestinal organoid-derived exosomes according to the present invention have the effects of improving pancreatic-related markers and inflammation-related factors in a beta-cell damage model treated with palmitic acid, reducing the expression of oxidative stress-related factors, and restoring insulin secretion ability, and thus can be effectively used in the treatment of various diseases related to pancreatic beta-cell dysfunction, including diabetes.
Absstract of: WO2026187690A1
The present disclosure generally relates to cell therapies and related methods, kits, assays, tests and devices for treatment of diabetes, including Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D), and other conditions characterized by insulin deficiency.
Absstract of: US20260263559A1
0000 Described herein are compositions comprising a combination of active agents, such as recombinant fibroblast growth factor-7 (FGF-7), recombinant follistatin, recombinant interleukin-6 (IL-6), recombinant transforming growth factor beta-1 (TGFβ-1), recombinant urokinase receptor (uPAR), and a carrier, which compositions may further comprise recombinant angiopoietin-1 (ANG-1), recombinant hepatocyte growth factor (HGF), recombinant insulin, and/or recombinant vascular endothelial growth factor (VEGF). Also provided herein are methods of treating wounds, accelerating healing of a wound, accelerating angiogenesis, and/or reducing scarring, as well as methods for culturing cells in vitro, and for cell delivery in vivo, using compositions of the present invention.
Absstract of: WO2026184101A1
A method and apparatus for real-time calculation of a gastric emptying rate of a patient. The method comprises: S1, using a fluorescence indicator method to determine a gastric emptying trend line representing a gastric emptying rate of a patient; S2, monitoring blood glucose of the patient in real time; and S3, correcting the gastric emptying rate of the patient in a personalized manner on the basis of a real-time blood glucose monitoring value of the patient. The apparatus comprises: a fluorescence measurement unit, configured to perform fluorescence measurement on a patient by using a fluorescence indicator method, to determine a gastric emptying trend line representing a gastric emptying rate of the patient; a blood glucose measurement unit, configured to monitor blood glucose of the patient in real time; and a calculation unit, configured to correct the gastric emptying rate of the patient in a personalized manner on the basis of a real-time blood glucose monitoring value of the patient, wherein the corrected gastric emptying rate can be calculated using a specific formula, and the specific formula incorporates a blood glucose rate-of-change coefficient for quantifying the impact of blood glucose changes on the gastric emptying rate, as well as the rate of change of blood glucose.
Absstract of: AU2025232283A1
An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg/dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg/dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.
Absstract of: EP4802998A2
0001 This application discloses a continuous glucose concentration monitoring method based on a multi-working-electrode system, a continuous glucose concentration monitoring device based on a multi-working-electrode system, a computer program, a computer-readable medium and a method for preparing continuous glucose concentration monitoring device based on a multi-working-electrode system. The method includes: obtaining, by using a first working electrode, a first current value used for representing a glucose concentration of a host, and obtaining, by using a second working electrode, a second current value used for representing the glucose concentration of the host, where the first working electrode and the second working electrode are separately and independently disposed on a same substrate, and the first working electrode includes a first parameter, and the second working electrode includes a second parameter; and determining a target glucose concentration according to the first current value as well as the first parameter and/or the second parameter as well as the second current value, where the first parameter is determined based on the second parameter and the second current value. In this application, a measurement error caused by a single electrode is reduced by using the first working electrode and the second working electrode, to improve accuracy of glucose concentration monitoring, and reduce a monitoring result deviation caused by an electrode difference.
Absstract of: EP4803002A1
0001 According to one embodiment, a wearable electronic device comprises a first sensor, at least one second sensor, a memory, a display, a communication circuit and at least one processor, wherein the memory can store instructions that, when executed by the at least one processor, cause the wearable electronic device to: identify, on the basis of a first sensing value identified through the at least one second sensor, a first time point so as to measure first blood glucose data of a user wearing the wearable electronic device; use an external device at the first time point so as to display, through the display, first guide information for allowing the blood glucose of the user to be measured; measure, through the first sensor, a second sensing value indicating a first biometric signal of the user at the first time point; acquire, through the communication circuit, information indicating a first blood glucose value of the user measured at the first time point by the external device; and acquire, on the basis of the first blood glucose value and a second sensing value indicating the first biometric signal, calibration data for determining a blood glucose value of the user on the basis of sensing values indicating biometric signals of the user to be measured using the first sensor.
Absstract of: US12727758B1
A modular diagnostic system is disclosed for acquiring Raman spectral data from tear film and analyzing biochemical signatures using Artificial Intelligence (AI). The system includes a Raman excitation source, a spectral acquisition module, and a processing engine configured to perform baseline correction, feature extraction, and AI-based classification. The system enables real-time, non-invasive diagnostics for dry eye disease, diabetes, metabolic disease, pharmacologic agents, and other conditions. The system supports longitudinal tracking and EMR integration. Real-time outputs support clinical diagnosis, treatment guidance, and longitudinal monitoring.
Absstract of: WO2020067628A1
The present invention relates to a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device: includes a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use thereof, without additional work for connecting a separate transmitter, and easier maintenance; and is activated by a user's operation after the body attachment unit is attached to the body, so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Absstract of: US20260260730A1
A method of administering insulin includes receiving scheduled glucose time intervals and obtaining glucose data of a patient that includes glucose measurements, glucose times, and insulin dosages previously administered by the patient. The method also includes applying a set of filters to identify which of the glucose measurements associated with at least one of the scheduled time intervals are usable and which of the glucose measurements associated with the at least one scheduled time interval are unusable. The method also includes aggregating the glucose measurements associated with the at least one scheduled time interval identified as usable to determine a representative aggregate glucose measurement and determining a next recommended insulin dosage for the patient based on the representative aggregate glucose measurement and the insulin dosages previously administered by the patient.
Absstract of: WO2026182236A1
The present disclosure provides, for example, a cell cryopreservation composition capable of protecting cells during cell freezing without substantially adding an organic solvent cell cryopreservation agent. A cell cryopreservation composition according to the present disclosure contains a sugar or a derivative thereof and/or a surfactant.
Absstract of: WO2026179772A1
A blood glucose assessment method, a user interface and a related apparatus. The blood glucose assessment method can acquire a PPG signal of a user, and then display a blood glucose result of the user obtained by assessment on the basis of the PPG signal, the blood glucose result indicating the stage at which the user falls in the progression from normal blood glucose to diabetes. The method takes into account that there is still a stage of development before normal blood glucose is converted into diabetes, thereby achieving more refined assessment of the blood glucose of users, so that the users achieve more refined self-management of blood glucose.
Absstract of: WO2026182442A1
Disclosed is an electronic device. The electronic device comprises: at least one sensor; memory storing a machine learning model and instructions; and at least one processor. When the instructions are individually or collectively executed by the at least one processor, the electronic device: obtains a PPG signal of a user by using the at least one sensor; performs preprocessing on the PPG signal by using a filter; obtains a power spectrum by converting the preprocessed PPG signal into frequency over time; obtains an average spectrum power for each frequency by calculating an average value of the obtained power spectrum over time; and obtains information about diabetes of the user by inputting the obtained average spectrum power for each frequency to the machine learning model.
Absstract of: US20260257014A1
Disclosed herein are systems and methods incorporating an ambulatory infusion pump and a CGM. These systems that can include software and related methods to provide improved automated insulin delivery algorithms that enable the algorithms to safely continue delivering insulin for some time periods of missing or known inaccurate glucose values.
Absstract of: US20260258368A1
0000 Methods are provided for in vitro selection of metabolic selection of metabolically selectable mammalian cells that don't require exogenous glucose and glutamine in culture. Such cells may be glycogen-storing mammalian cells, including without limitation hepatocytes. Metabolic selection provides an approach to rapidly kill non-selectable cells by withholding specific nutrients from the culture medium.
Absstract of: EP4800696A1
The present invention relates to a computer implemented training method for training a first artificial intelligence agent for glycemic control of a patient and also relates to a computer implemented method of determining an insulin dose value for a patient next to administer and for administration by an insulin administration device based on a treatment algorithm comprising a first artificial intelligence agent.
Absstract of: EP4800372A2
0001 A continuous glucose monitoring system may utilize electrode current (Isig) signals, Electrochemical Impedance Spectroscopy (EIS), and Vcntr values to optimize sensor glucose (SG) calculation in such a way as to enable reduction of the need for blood glucose (BG) calibration requests from users.
Absstract of: EP4800534A2
The subject matter disclosed herein provides methods for presenting glucose level data. Glucose data for a patient may be received. A current glucose level and a rate of change of the current glucose level may be determined based on the received glucose data. A first interface may be displayed on a screen of a device. The first interface may include a unitary icon. The unitary icon may display the current glucose level and a visualization of the rate of change. Related apparatus, systems, techniques, and articles are also described.
Nº publicación: EP4799662A1 02/09/2026
Applicant:
MEDTRUM TECH INC [CN]
Medtrum Technologies Inc.
Absstract of: EP4799662A1
The invention discloses a method and system for postprandial insulin infusion based on identifiable feature of diabetic, acquiring a food image by an imaging mechanism, and analyzing the food image by the food image recognition model to obtain food data, retrieving a narrow insulin algorithm adapted to the patient's own identifiable features from the cluster of narrow insulin algorithms according to the identifiable features of the patient, for calculation of insulin infusion amount during meals, compared to the preset insulin algorithm, the narrow insulin algorithm is more applicable to the physiological characteristics and living habit of the patient, the calculated postprandial insulin infusion amount is more accurate, and is beneficial for the treatment of diabetic.
BOPI
Electronic site
